Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred Hensel

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
European Journal of Haematology|May 4, 2017
Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS studyMarcel Reiser, Michael Borte, Dörte Huscher, et al.
Leukemia & Lymphoma|April 15, 2014
Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemiaIsabelle Herth, Manfred Hensel, Michael Rieger, et al.
European Journal of Haematology|March 25, 2010
Clinical outcome of patients with follicular lymphoma and bulky disease after rituximab-CHOP immunochemotherapy with and without consolidating radiotherapyFabienne McClanahan, Thomas Hielscher, Michael Rieger, et al.
European Journal of Haematology|March 26, 2018
Outcome after high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive B-cell non-Hodgkin's lymphomaKatharina Kriegsmann, Michael Rieger, Mark-Alexander Schwarzbich, et al.
The Lancet. Oncology|July 7, 2007
JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemiaAlwin Krämer, Andreas Reiter, Jens Kruth, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 5, 2019
Patients With Malignant Lymphoma and HIV Infection Experiencing Remission After First-Line Treatment Have an Excellent PrognosisKatharina Kriegsmann, Julia S Klee, Manfred Hensel, et al.
Annals of Hematology|July 1, 2008
Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone)Carsten Zwick, Josef Birkmann, Norma Peter, et al.
Blood|October 31, 2007
Specific recruitment of regulatory T cells into the CSF in lymphomatous and carcinomatous meningitisJürgen Haas, Laila Schopp, Brigitte Storch-Hagenlocher, et al.
European Journal of Haematology|February 3, 2018
Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practiceMarcel Reiser, Steffen Dörfel, Manfred Hensel, et al.
BMC Immunology|July 1, 2020
Health status and infections in patients with symptomatic primary and secondary immunoglobulin G (IgG) deficiencies receiving intravenous IgG replacementRudolf Weide, Roland Schnell, Christof Schardt, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
European Journal of Haematology|May 4, 2017
Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS studyMarcel Reiser, Michael Borte, Dörte Huscher, et al.
Leukemia & Lymphoma|April 15, 2014
Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemiaIsabelle Herth, Manfred Hensel, Michael Rieger, et al.
European Journal of Haematology|March 25, 2010
Clinical outcome of patients with follicular lymphoma and bulky disease after rituximab-CHOP immunochemotherapy with and without consolidating radiotherapyFabienne McClanahan, Thomas Hielscher, Michael Rieger, et al.
European Journal of Haematology|March 26, 2018
Outcome after high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive B-cell non-Hodgkin's lymphomaKatharina Kriegsmann, Michael Rieger, Mark-Alexander Schwarzbich, et al.
The Lancet. Oncology|July 7, 2007
JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemiaAlwin Krämer, Andreas Reiter, Jens Kruth, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 5, 2019
Patients With Malignant Lymphoma and HIV Infection Experiencing Remission After First-Line Treatment Have an Excellent PrognosisKatharina Kriegsmann, Julia S Klee, Manfred Hensel, et al.
Annals of Hematology|July 1, 2008
Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone)Carsten Zwick, Josef Birkmann, Norma Peter, et al.
Blood|October 31, 2007
Specific recruitment of regulatory T cells into the CSF in lymphomatous and carcinomatous meningitisJürgen Haas, Laila Schopp, Brigitte Storch-Hagenlocher, et al.
European Journal of Haematology|February 3, 2018
Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practiceMarcel Reiser, Steffen Dörfel, Manfred Hensel, et al.
BMC Immunology|July 1, 2020
Health status and infections in patients with symptomatic primary and secondary immunoglobulin G (IgG) deficiencies receiving intravenous IgG replacementRudolf Weide, Roland Schnell, Christof Schardt, et al.
Pageof 6